Table 1.
Characteristics of the Study Cohort on Infant-Level
| Number of infants (eyes) | 101 (201) |
| Number of OCT imaging sessionsa | 631 |
| Number of OCT imaging sessions per infant, median (Q1–Q3) | 5 (4–8) |
| Gestational age, mean ± SD, wks | 28.0 ± 2.7 |
| Birth weight, mean ± SD, gm | 979.5 ± 290.4 |
| Sex, n (%) | |
| Female | 52 (51.5) |
| Race, n (%) | |
| African-American | 47 (46.5) |
| Asian | 5 (5.0) |
| White | 45 (44.6) |
| More than one | 4 (4.0) |
| Ethnicity, n (%) | |
| Non-Hispanic | 92 (91.1) |
| PMA at the first imaging session, median (Q1–Q3), wks | 33.1 (31.7–34.4) |
| PMA at the last imaging session, median (Q1–Q3), wksb | 47.1 (38.5–58.2) |
| Maximum ROP stage, n (%)c | |
| Stage 0 | 43 (42.6) |
| Stage 1 | 16 (15.8) |
| Stage 2 | 26 (25.7) |
| Stage 3 | 15 (14.9) |
| Stage 4 | 1 (1.0) |
| Maximum plus disease, n (%)c | |
| None | 83 (82.2) |
| Pre-plus disease | 7 (6.9) |
| Plus disease | 11 (10.9) |
| Any treatment for ROP, n (%)d | |
| None | 89 (88.1) |
| Laser photocoagulation | 3 (3.0) |
| Bevacizumab and laser photocoagulation | 9 (8.9) |
OCT = optical coherence tomography; PMA = postmenstrual age; Q1 = first quartile; Q3 = third quartile; ROP = retinopathy of prematurity; SD = standard deviation.
a
Among 631 OCT imaging sessions, 533 (84.5%) sessions have RNFL thickness measurements from both eyes of the same infants.
b
The last imaging session before or on 60 weeks and 6 days PMA. Imaging sessions after the treatment for retinopathy of prematurity were excluded from the analysis, which contributed to the large interquartile range of PMA at the last imaging session.
c
The highest stage across all visits in the worse eye for each infant.
d
The ROP treatment that an infant received regardless of the eye laterality.